Exemestane

Generic Name
Exemestane
Brand Names
Aromasin
Drug Type
Small Molecule
Chemical Formula
C20H24O2
CAS Number
107868-30-4
Unique Ingredient Identifier
NY22HMQ4BX
Background

Exemestane is an oral steroidal aromatase inhibitor used in the adjuvant treatment of hormonally-responsive (also called hormone-receptor-positive, estrogen-responsive) breast cancer in postmenopausal women. It irreversibly binds to the active site of the enzyme resulting in permanent inhibition.

Indication

For the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.

Associated Conditions
Stage I Breast Cancer, Refractory, advanced Breast cancer
Associated Therapies
-
Clinical Trials
Related News

Aromasin (Exemestane) in Patients With Recurrent or Refractory Stage II - IV Epithelial Ovarian Cancer

Phase 2
Completed
Conditions
Ovarian Cancer
First Posted Date
2005-12-02
Last Posted Date
2010-03-02
Lead Sponsor
Ottawa Hospital Research Institute
Target Recruit Count
30
Registration Number
NCT00261027
Locations
🇨🇦

Ottawa Regional Cancer Center, Ottawa, Ontario, Canada

Fulvestrant With or Without Anastrozole or Exemestane Alone in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer

Phase 3
Conditions
Breast Cancer
First Posted Date
2005-11-15
Last Posted Date
2011-05-17
Lead Sponsor
Institute of Cancer Research, United Kingdom
Target Recruit Count
750
Registration Number
NCT00253422
Locations
🇬🇧

Royal Marsden - London, London, England, United Kingdom

🇬🇧

Institute of Cancer Research - Sutton, Sutton, England, United Kingdom

Exemestane With Celecoxib as Neoadjuvant Treatment in Postmenopausal Women With Stage II, III, and IV Breast Cancer

First Posted Date
2005-09-20
Last Posted Date
2015-06-30
Lead Sponsor
Ohio State University Comprehensive Cancer Center
Target Recruit Count
22
Registration Number
NCT00201773
Locations
🇺🇸

Ohio State University, Columbus, Ohio, United States

Exemestane in Combination With Fulvestrant in Postmenopausal Women With Hormone Sensitive Advanced Breast Cancer

Phase 2
Completed
Conditions
Breast Cancer
Interventions
Drug: Exemestane
Drug: Fulvestrant
First Posted Date
2005-09-20
Last Posted Date
2018-07-26
Lead Sponsor
Ohio State University Comprehensive Cancer Center
Target Recruit Count
40
Registration Number
NCT00201864
Locations
🇺🇸

Ohio State University, Columbus, Ohio, United States

Hormone Therapy and Combination Chemotherapy Before and After Surgery in Treating Patients With Stage I-IIIA Breast Cancer

First Posted Date
2005-09-19
Last Posted Date
2017-07-11
Lead Sponsor
University of Washington
Target Recruit Count
28
Registration Number
NCT00194792
Locations
🇺🇸

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Aromasin Vs Arimidex Study As Initial Hormonal Therapy In Postmenopausal Women With Advanced/Recurrent Breast Cancer

Phase 3
Completed
Conditions
Breast Neoplasms
Interventions
Drug: exemestane
Drug: anastrozole
First Posted Date
2005-09-02
Last Posted Date
2012-01-25
Lead Sponsor
Pfizer
Target Recruit Count
298
Registration Number
NCT00143390
Locations
🇯🇵

Pfizer Investigational Site, Shizuoka, Japan

Exemestane Versus Anastrozole as First Line Hormone Therapy in Postmenopausal Metastatic Breast Cancer Patients

Phase 2
Completed
Conditions
Breast Cancer
Interventions
Drug: Anastrozole
Drug: Exemestane
First Posted Date
2005-08-10
Last Posted Date
2023-03-06
Lead Sponsor
Spanish Breast Cancer Research Group
Target Recruit Count
103
Registration Number
NCT00128843
Locations
🇪🇸

Ruber Internacional, Madrid, Spain

🇪🇸

H Universitario Miguel Servet, Zaragoza, Spain

🇪🇸

Hospital Donostia, Donostia-San Sebastián, Guipúzcoa, Spain

and more 10 locations

Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer

Phase 3
Completed
Conditions
Breast Cancer
Interventions
Drug: exemestane
First Posted Date
2004-05-17
Last Posted Date
2023-08-25
Lead Sponsor
NCIC Clinical Trials Group
Target Recruit Count
4560
Registration Number
NCT00083174
Locations
🇺🇸

Trinity Medical Center, Moline, Illinois, United States

🇺🇸

University of California, San Diego, La Jolla, California, United States

🇺🇸

Providence Alaska Medical Center, Anchorage, Alaska, United States

and more 73 locations

Exemestane Plus Goserelin in Treating Premenopausal Women With Metastatic Breast Cancer

Phase 2
Completed
Conditions
Breast Cancer
First Posted Date
2004-04-21
Last Posted Date
2016-03-11
Lead Sponsor
NYU Langone Health
Registration Number
NCT00010010
Locations
🇺🇸

NYU School of Medicine's Kaplan Comprehensive Cancer Center, New York, New York, United States

Neoadjuvant and Adjuvant Exemestane in Treating Postmenopausal Women With Locally Advanced Hormone Receptor-Positive Breast Cancer

First Posted Date
2004-04-08
Last Posted Date
2013-07-10
Lead Sponsor
Robert H. Lurie Cancer Center
Registration Number
NCT00080613
Locations
🇺🇸

Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy